TGFB1 and cancer: Moreover, recent research has indicated that genetic manipulation of platelets or the use of antiplatelet pharmacological agents may enhance the effectiveness of adaptive T-cell therapies for cancer by targeting the GARP-TGFβ axis [57,58].